Restless Leg Syndrome

restiffic_lifestyle_couch_RLS1

About restiffic® foot wraps

restiffic is one of the only drug-free products that assist in treating Restless Leg Syndrome (RLS) symptoms. restiffic was developed by a clinician who suffered from RLS for decades. Patients only wear the product when the RLS symptoms occur. It is a temporary device to help them “unwire” their restless symptoms. Please watch Mary’s story to learn how this treatment was conceived.

Explore the multiple education and training programs provided by medi®

Meet physicians who have successfully treated RLS with restiffic

Success of restiffic

In the clinical trial, 69% of the patients had significant symptom reductions in the 8-week period. It is still not understood why some patients’ see results and others do not. Therefore, restiffic comes with a 30-day guarantee. Most patients will experience relief of symptoms within 48-72 hours. If results are not seen in the first 30 days of purchase, they can return it for a full refund.

How you can help

medi® receives continuous requests from patients seeking treatment and with questions on how to obtain the restiffic product. Because the restiffic foot wrap is a medical device cleared by the FDA, it requires a prescription for purchase and use. medi and the restiffic team will supply you with patient brochures, a copy of the clinical trial, a sleep journal for patient use, prescription pads and a sample for use in your clinic. If you are interested in helping patients in your area find the proper care for their Restless Leg Syndrome, please complete the form below.

Please reach out to us for any demo, in-service training, literature, and webinar needs. We are always taking requests to provide the best support available.

Education Opportunities

view more here

Education Opportunities

view more here

Looking for a certain medi product solution? Our product catalog features a robust filtering system that enables you to search and find what you are looking for with ease.

Share this content:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Scroll to Top